Serial No.: 10/541,657 Filed: March 3, 2006

Page : 2 of 49

## AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions and listings of claims in the application.

## **Listing of Claims**

1. (previously presented) A compound selected from compounds of Formula (Ia) and pharmaceutically acceptable salts, hydrates, and solvates thereof:

wherein:

A and B are independently  $C_{1-3}$  alkylene optionally substituted with 1 to 4 methyl groups;

D is CR<sub>2</sub>R<sub>3</sub> or N-R<sub>2</sub>;

V is absent;

W is NR<sub>4</sub> or O;

X is N;

Y is N;

Z is selected from the group consisting of  $C_{1-5}$  acyl,  $C_{1-8}$  alkyl,  $C_{1-4}$  alkylcarboxamide, amino, cyano,  $C_{4-8}$  diacylamino,  $C_{2-6}$  dialkylsulfonamide, formyl, halogen, heterocyclic, and nitro wherein  $C_{1-8}$  alkyl and  $C_{1-5}$  acyl are each optionally substituted with 1 or 2 groups selected from the group consisting of  $C_{2-4}$  dialkylamino, hydroxy, and halogen; or

Z is selected from the group consisting of nitro, amino, formyl, NHC(O)CF<sub>3</sub>, Br, NHC(O)CH<sub>3</sub>, N(C(O)CH<sub>3</sub>)<sub>2</sub>, N(S(O)<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, CH<sub>3</sub>, [1,3]dioxolan-2-yl, CH<sub>2</sub>OH, CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, and C(O)CH<sub>3</sub>; or

Z is a group of Formula (A):

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 3 of 49

wherein:

R<sub>7</sub> is H, C<sub>1-8</sub> alkyl or C<sub>3-6</sub> cycloalkyl; and R<sub>8</sub> is H, nitro or nitrile;

Ar<sub>1</sub> is aryl or heteroaryl wherein each is optionally substituted with R<sub>9</sub>-R<sub>13</sub>;

R<sub>1</sub> is selected from the group consisting of H, C<sub>1-4</sub> alkoxy, C<sub>1-8</sub> alkyl, C<sub>2-6</sub> alkynyl, amino, C<sub>3-6</sub> cycloalkyl, and C<sub>1-4</sub> haloalkyl;

R<sub>2</sub> is selected from the group consisting of C<sub>1-5</sub> acyl, C<sub>1-5</sub> acyloxy, C<sub>1-4</sub> alkoxy, C<sub>1-8</sub> alkyl, C<sub>1-4</sub> alkylcarboxamide, C<sub>1-4</sub> alkylthiocarboxamide, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> alkylthio, amino, carbo-C<sub>1-6</sub>-alkoxy, carboxamide, carboxy, C<sub>3-6</sub>-cycloalkyl, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> haloalkyl, halogen, hydroxyl, CH<sub>2</sub>OCH<sub>2</sub>-cyclopropyl, CH<sub>2</sub>OCH<sub>2</sub>-cyclobutyl, CH<sub>2</sub>OCH<sub>2</sub>-cyclopentyl, CH<sub>2</sub>OCH<sub>2</sub>-cyclopentyl, CH<sub>2</sub>OCH<sub>2</sub>-cyclopropyl, CH<sub>2</sub>OCH<sub>2</sub>-cyclopentyl, CH<sub>2</sub>OCH<sub>2</sub>-cyclobutyl, CH<sub>2</sub>OCH<sub>2</sub>-cyclobexyl, CH<sub>2</sub>OCH<sub>2</sub>-cyclobexyl, CH<sub>2</sub>CH<sub>2</sub>-cyclopentyl, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>-cyclopentyl, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>-cyclopentyl, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>-cyclopentyl, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>-cyclobexyl, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>-cyclobexyl, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>-cyclobexyl, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>-cyclopentyl, and CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>-cyclohexyl; or

 $R_2$  is  $C_{1-8}$  alkyl or heteroaryl, each optionally substituted with 1 to 5 substituents selected from the group consisting of  $C_{1-5}$  acyloxy,  $C_{1-4}$  alkoxy,  $C_{1-8}$  alkyl,  $C_{1-4}$  alkylsulfonyl, carbo- $C_{1-6}$ -alkoxy, carboxamide, carboxy,  $C_{3-6}$ -cycloalkyl,  $C_{3-6}$ -cycloalkyl- $C_{1-3}$ -alkylene,  $C_{3-6}$ -cycloalkyl- $C_{1-3}$ -heteroalkylene, and hydroxyl; or

R<sub>2</sub> is -Ar<sub>2</sub>-Ar<sub>3</sub> wherein Ar<sub>2</sub> and Ar<sub>3</sub> are independently aryl or heteroaryl each optionally substituted with 1 to 5 substituents selected from the group consisting of H, C<sub>1-5</sub> acyl, C<sub>1-5</sub> acyloxy, C<sub>1-4</sub> alkoxy, C<sub>1-8</sub> alkyl, C<sub>1-4</sub> alkylcarboxamide, C<sub>1-4</sub> alkylthiocarboxamide, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> alkylthio, amino, carbo-C<sub>1-6</sub>-alkoxy, carboxamide, carboxy, cyano, C<sub>3-6</sub>-cycloalkyl, C<sub>2-6</sub> dialkylcarboxamide, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> haloalkyl, halogen, hydroxyl and nitro; or

R<sub>2</sub> is a group of Formula (B):

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 4 of 49

wherein:

 $R_{14}$  is  $C_{1-8}$  alkyl or  $C_{3-6}$  cycloalkyl; and  $R_{15}$  is F, Cl, Br or CN; or  $R_2$  is a group of Formula (C):

wherein:

G is C=O, CR<sub>16</sub>R<sub>17</sub>, O, S, S(O), or S(O)<sub>2</sub>; wherein

R<sub>16</sub> and R<sub>17</sub> are independently H or C<sub>1-8</sub> alkyl; and

Ar<sub>4</sub> is phenyl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of C<sub>1-5</sub> acyl, C<sub>1-5</sub> acyloxy, C<sub>1-4</sub> alkoxy, C<sub>1-8</sub> alkyl, C<sub>1-4</sub> alkylcarboxamide, C<sub>1-4</sub> alkylthiocarboxamide, C<sub>1-4</sub> alkylsulfonamide, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylthioureyl, C<sub>1-4</sub> alkylureyl, amino, carbo-C<sub>1-6</sub>-alkoxy, carboxamide, carboxy, cyano, C<sub>3-6</sub>-cycloalkyl, C<sub>2-6</sub> dialkylcarboxamide, C<sub>1-4</sub> dialkylthiocarboxamide, C<sub>2-6</sub> dialkylsulfonamide, C<sub>1-4</sub> alkylthioureyl, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> haloalkylsulfinyl, C<sub>1-4</sub> haloalkylsulfonyl, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> haloalkylthio, halogen, heteroaryl, hydroxyl, hydroxylamino and nitro;

 $R_3$  is H,  $C_{1-8}$  alkyl,  $C_{1-4}$  alkoxy, halogen or hydroxyl;  $R_4$  is H or  $C_{1-8}$  alkyl;

R<sub>5</sub> and R<sub>6</sub> are independently H, C<sub>1-8</sub> alkyl or halogen;

 $R_9$  is selected from the group consisting of  $C_{1-5}$  acyl,  $C_{1-5}$  acyloxy,  $C_{2-6}$  alkenyl,  $C_{1-4}$  alkoxy,  $C_{1-8}$  alkyl,  $C_{1-4}$  alkylamino,  $C_{1-4}$  alkylcarboxamide,  $C_{2-6}$  alkynyl,  $C_{1-4}$  alkylsulfonamide,  $C_{1-4}$  alkylsulfinyl,  $C_{1-4}$  alkylsulfonyl,  $C_{1-4}$  alkylthio,  $C_{1-4}$  alkylureyl, amino, arylsulfonyl, carbo- $C_{1-6}$ -alkoxy, carboxamide, carboxy, cyano,  $C_{3-6}$  cycloalkyl,  $C_{2-6}$  dialkylamino,  $C_{2-6}$  dialkylsulfonamide, halogen,  $C_{1-4}$  haloalkoxy,  $C_{1-4}$  haloalkyl,  $C_{1-4}$ 

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 5 of 49

haloalkylsulfinyl, C<sub>1-4</sub> haloalkylsulfonyl, C<sub>1-4</sub> haloalkylthio, heterocyclic, heterocyclicsulfonyl, heteroaryl, hydroxyl, nitro, C<sub>4-7</sub> oxo-cycloalkyl, phenoxy, phenyl, sulfonamide and sulfonic acid, and wherein C<sub>1-5</sub> acyl, C<sub>1-4</sub> alkoxy, C<sub>1-8</sub> alkyl, C<sub>1-4</sub> alkylsulfonamide, alkylsulfonyl, arylsulfonyl, heteroaryl, phenoxy and phenyl are each optionally substituted with 1 to 5 substituents selected independently from the group consisting of C<sub>1-5</sub> acyl, C<sub>1-5</sub> acyloxy, C<sub>2-6</sub> alkenyl, C<sub>1-4</sub> alkoxy, C<sub>1-8</sub> alkyl, C<sub>1-4</sub> alkylcarboxamide, C<sub>2-6</sub> alkynyl, C<sub>1-4</sub> alkylsulfonamide, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-6</sub> dialkylcarboxamide, halogen, C<sub>1-6</sub>-alkoxy, carboxamide, carboxy, cyano, C<sub>3-6</sub> cycloalkyl, C<sub>2-6</sub> dialkylcarboxamide, halogen, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> haloalkylsulfinyl, C<sub>1-4</sub> haloalkylsulfonyl, C<sub>1-4</sub> haloalkylsulfonyl, C<sub>1-4</sub> haloalkylsulfonyl, or

 $R_9$  is a group of Formula (**D**):

wherein:

"p" and "r" are independently 0, 1, 2 or 3; and

 $R_{18}$  is H,  $C_{1-5}$  acyl,  $C_{2-6}$  alkenyl,  $C_{1-8}$  alkyl,  $C_{1-4}$  alkylcarboxamide,  $C_{2-6}$  alkynyl,  $C_{1-4}$  alkylsulfonamide, carbo- $C_{1-6}$ -alkoxy, carboxamide, carboxy, cyano,  $C_{3-6}$  cycloalkyl,  $C_{2-6}$  dialkylcarboxamide, halogen, heteroaryl or phenyl, and wherein the heteroaryl and phenyl are each optionally substituted with 1 to 5 substituents selected independently from the group consisting of  $C_{1-4}$  alkoxy, amino,  $C_{1-4}$  alkylamino,  $C_{2-6}$  alkynyl,  $C_{2-8}$  dialkylamino, halogen,  $C_{1-4}$  haloalkoxy,  $C_{1-4}$  haloalkyl and hydroxyl; and

R<sub>10</sub>-R<sub>13</sub> are independently selected from the group consisting of C<sub>1-5</sub> acyl, C<sub>1-5</sub> acyloxy, C<sub>2-6</sub> alkenyl, C<sub>1-4</sub> alkoxy, C<sub>1-8</sub> alkyl, C<sub>1-4</sub> alkylcarboxamide, C<sub>2-6</sub> alkynyl, C<sub>1-4</sub> alkylsulfonamide, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylureyl, carbo-C<sub>1-6</sub>-alkoxy, carboxamide, carboxy, cyano, C<sub>3-6</sub> cycloalkyl, C<sub>2-6</sub> dialkylcarboxamide, halogen, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> haloalkylsulfinyl, C<sub>1-4</sub> haloalkylsulfonyl, C<sub>1-4</sub> haloalkylthio, hydroxyl and nitro; or

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 6 of 49

two adjacent  $R_{10}$ - $R_{11}$  groups together with  $Ar_1$  form a 5, 6 or 7 membered cycloalkyl, cycloalkenyl or heterocyclic group wherein the 5, 6 or 7 membered group is optionally substituted with halogen.

- 2. (original) The compound according to claim 1 wherein W is NR<sub>4</sub>.
- 3. (original) The compound according to claim 2 wherein  $R_4$  is H.
- 4. (withdrawn) The compound according to claim 2 wherein R<sub>4</sub> is CH<sub>3</sub> or CH<sub>2</sub>CH<sub>3</sub>.
- 5. (withdrawn) The compound according to claim 1 wherein W is O.
- 6-11. (cancelled)
- 12. (previously presented) The compound according to claim 1 wherein A is ethylene and B is methylene.
- 13. (previously presented) The compound according to claim 1 wherein A is propylene and B is methylene.
- 14. (previously presented) The compound according to claim 1 wherein A and B are both ethylene wherein A and B are optionally substituted with 1 to 4 methyl groups.
- 15. (cancelled)
- 16. (previously presented) The compound according to claim 1 wherein D is CR<sub>2</sub>R<sub>3</sub>.
- 17. (previously presented) The compound according to claim 16 wherein R<sub>2</sub> is selected from the group consisting of C<sub>1-5</sub> acyl, C<sub>1-5</sub> acyloxy, C<sub>1-4</sub> alkoxy, C<sub>1-8</sub> alkyl, C<sub>1-4</sub> alkylcarboxamide, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> alkylthio, amino, carbo-C<sub>1-6</sub>-alkoxy, carboxamide, carboxyl, C<sub>3-6</sub> cycloalkyl, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> haloalkyl, halogen and hydroxyl.
- 18. (original) The compound according to claim 17 wherein R<sub>2</sub> is selected from the group consisting of C(O)CH<sub>3</sub>, C(O)CH<sub>2</sub>CH<sub>3</sub>, C(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, C(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>,

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 7 of 49

OC(O)CH<sub>3</sub>, OC(O)CH<sub>2</sub>CH<sub>3</sub>, OC(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, OCH(CH<sub>3</sub>)<sub>2</sub>, OCH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, CH(CH<sub>3</sub>)(CH<sub>2</sub>CH<sub>3</sub>), CH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, CO<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, CO<sub>2</sub>CH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, and CO<sub>2</sub>H.

- 19. (original) The compound according to claim 17 wherein R<sub>2</sub> is selected from the group consisting of S(O)<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, S(O)<sub>2</sub>CH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, hydroxyl, and F.
- 20. (original) The compound according to claim 16 wherein R<sub>2</sub> is C<sub>1-8</sub> alkyl, or heteroaryl each optionally substituted with 1 to 5 substituents selected from the group consisting of C<sub>1-5</sub> acyloxy, C<sub>1-4</sub> alkoxy, C<sub>1-8</sub> alkyl, C<sub>1-4</sub> alkylsulfonyl, carbo-C<sub>1-6</sub>-alkoxy, carboxamide, carboxy, C<sub>3-6</sub>-cycloalkyl, C<sub>3-6</sub>-cycloalkyl-C<sub>1-3</sub>-alkylene, C<sub>3-6</sub>-cycloalkyl-C<sub>1-3</sub>-heteroalkylene, and hydroxyl.

- 23. (original) The compound according to claim 20 wherein R<sub>2</sub> is selected from the group consisting of 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 3-ethyl-1,2,4-oxadiazol-5-yl, 3-isopropyl-1,2,4-oxadiazol-5-yl, 3-propyl-1,2,4-oxadiazol-5-yl, 3-t-butyl-1,2,4-oxadiazol-5-yl, and 3-cyclopropyl-1,2,4-oxadiazol-5-yl.
- 24. (original) The compound according to claim 16 wherein R<sub>2</sub> is -Ar<sub>2</sub>-Ar<sub>3</sub> wherein Ar<sub>2</sub> and Ar<sub>3</sub> are independently aryl or heteroaryl each optionally substituted with 1 to 5 substituents selected from

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 8 of 49

the group consisting of  $C_{1-5}$  acyl,  $C_{1-5}$  acyloxy,  $C_{1-4}$  alkoxy,  $C_{1-8}$  alkyl,  $C_{1-4}$  alkylcarboxamide,  $C_{1-4}$  alkylsulfinyl,  $C_{1-4}$  alkylsulfonyl,  $C_{1-4}$  alkylthio, amino, carbo- $C_{1-6}$ -alkoxy, carboxamide, carboxy, cyano,  $C_{3-6}$ -cycloalkyl,  $C_{2-6}$  dialkylcarboxamide,  $C_{1-4}$  haloalkoxy,  $C_{1-4}$  haloalkyl, halogen, hydroxyl and nitro.

- 25. (original) The compound according to claim 24 wherein Ar<sub>2</sub> is a heteroaryl and Ar<sub>3</sub> is phenyl.
- 26. (original) The compound according to claim 16 wherein  $R_2$  is Formula (C):

**(C)** 

wherein:

G is C=O,  $CR_{16}R_{17}$ , O, S, S(O), or S(O)<sub>2</sub>; wherein:

R<sub>16</sub> and R<sub>17</sub> are independently H or C<sub>1-2</sub> alkyl; and

Ar<sub>4</sub> is phenyl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of  $C_{1-4}$  alkoxy,  $C_{1-8}$  alkyl,  $C_{1-4}$  haloalkoxy,  $C_{1-4}$  haloalkyl, and halogen.

- 27. (original) The compound according to claim 26 wherein G is C=O, CH<sub>2</sub> or O.
- 28. (original) The compound according to claim 26 wherein G is S, S(O) or S(O)<sub>2</sub>.
- 29. (previously presented) The compound according claim 26 wherein Ar<sub>4</sub> is selected from the group consisting of pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl.
- 30. (previously presented) The compound according to claim 26 wherein  $Ar_4$  is 2-pyridyl.
- 31. (previously presented) The compound according to claim 26 wherein  $R_{16}$  and  $R_{17}$  are both H.
- 32. (previously presented) The compound according to claim 16 wherein R<sub>3</sub> is H.
- 33. (previously presented) The compound according claim 1 wherein D is N-R<sub>2</sub>.
- 34. (original) The compound according to claim 33 wherein R<sub>2</sub> is H, or carbo-C<sub>1-6</sub>-alkoxy.

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 9 of 49

35. (original) The compound according to claim 34 wherein R<sub>2</sub> is selected from the group consisting of CO<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, and CO<sub>2</sub>CH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>.

- 36. (original) The compound according to claim 33 wherein R<sub>2</sub> is C<sub>1-8</sub> alkyl optionally substituted with 1 to 5 substituents selected from the group consisting of C<sub>1-4</sub> alkylsulfonyl, carbo-C<sub>1-6</sub>-alkoxy, and carboxy.
- 37. (original) The compound according to claim 36 wherein R<sub>2</sub> is CH<sub>2</sub>CO<sub>2</sub>Et, or CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H.
- 38. (original) The compound according to claim 36 wherein R<sub>2</sub> is selected from the group consisting of CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> and CH<sub>2</sub>CH<sub>2</sub>S(O)<sub>2</sub>CH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>.
- 39. (previously presented) The compound according to claim 1 wherein Z is selected from the group consisting of C<sub>1-5</sub> acyl, C<sub>1-8</sub> alkyl, C<sub>1-4</sub> alkylcarboxamide, amino, cyano, C<sub>4-8</sub> diacylamino, C<sub>2-6</sub> dialkylsulfonamide, formyl, halogen, heterocyclic, and nitro wherein C<sub>1-8</sub> alkyl and C<sub>1-5</sub> acyl are each optionally substituted with 1, or 2 groups selected from the group consisting of C<sub>2-4</sub> dialkylmino, hydroxy, and halogen.
- 40. (original) The compound according to claim 39 wherein Z is selected from the group consisting of nitro, amino, formyl, NHC(O)CF<sub>3</sub>, Br, NHC(O)CH<sub>3</sub>, N(C(O)CH<sub>3</sub>)<sub>2</sub>, N(S(O)<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, CH<sub>3</sub>, [1,3]dioxolan-2-yl, CH<sub>2</sub>OH, CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, and C(O)CH<sub>3</sub>.
- 41. (previously presented) The compound according to claim 1 wherein  $R_1$  is selected from the group consisting of H,  $C_{1-8}$  alkyl, and amino.
- 42. (previously presented) The compound according to claim 1 wherein Ar<sub>1</sub> is phenyl optionally substituted with R<sub>9</sub>-R<sub>13</sub>.
- 43. (original) The compound according to claim 42 wherein R<sub>9</sub> is selected from the group consisting of C<sub>1-5</sub> acyl, C<sub>1-4</sub> alkoxy, C<sub>1-8</sub> alkyl, C<sub>1-4</sub> alkylcarboxamide, C<sub>2-6</sub> alkynyl, C<sub>1-4</sub> alkylsulfonamide, C<sub>2-6</sub> dialkylsulfonamide, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>2-6</sub> dialkylamino, C<sub>2-6</sub> dialkylsulfonamide, and carboxamide.

Serial No.: 10/541,657 Filed: March 3, 2006 Page: 10 of 49

44. (original) The compound according to claim 43 wherein R<sub>9</sub> is selected from the group consisting of C(O)CH<sub>3</sub>, C(O)CH<sub>2</sub>CH<sub>3</sub>, C(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, C(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, C(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, C(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, C(O)NHCH<sub>2</sub>CH<sub>3</sub>CH<sub>3</sub>, C(O)NHCH<sub>2</sub>CH<sub>3</sub>, C(O)NHCH<sub>2</sub>CH<sub>3</sub>, C(O)NHCH<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>NHCH<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>NHCH<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>NHCH<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>NHCH<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>NHCH<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>CH<sub>3</sub>CH<sub>3</sub>, S(O)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, SCH<sub>3</sub>, SCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, SCH<sub>2</sub>CH<sub>3</sub>, SCH<sub>2</sub>CH<sub>3</sub>, SCH<sub>2</sub>CH<sub>3</sub>, amino, S(O)<sub>2</sub>Ph, N(CH<sub>3</sub>)<sub>2</sub>, N(CH<sub>3</sub>)(Et), N(Et)<sub>2</sub> and C(O)NH<sub>2</sub>.

- 45. (original) The compound according to claim 42 wherein R<sub>9</sub> is selected from the group consisting of cyano, C<sub>3-6</sub> cycloalkyl, halogen, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> haloalkylsulfonyl, and C<sub>1-4</sub> haloalkylthio.
- 46. (original) The compound according to claim 45 wherein R<sub>9</sub> is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, Cl, F, Br, OCF<sub>3</sub>, OCHF<sub>2</sub>, OCH<sub>2</sub>CF<sub>3</sub>, CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>CF<sub>3</sub>, SCF<sub>3</sub>, SCHF<sub>2</sub> and SCH<sub>2</sub>CF<sub>3</sub>.
- 47. (original) The compound according to claim 42 wherein R<sub>9</sub> is selected from the group consisting of heterocyclic, heterocyclicsulfonyl, heteroaryl, hydroxy, C<sub>4-7</sub> oxo-cycloalkyl, phenoxy and phenyl.
- 48. (original) The compound according to claim 47 wherein R<sub>9</sub> is selected from the group consisting of morpholin-4-yl, thiomorpholin-4-yl, 1-oxo-1λ<sup>4</sup>-thiomorpholin-4-yl, 1,1-Dioxo-1λ<sup>6</sup>-thiomorpholin-4-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl, 4-ethyl-piperazin-1-yl, 4-propyl-piperazin-1-yl, piperidin-1-yl, pyrrolidin-1-yl, 2,5-dioxo-imidazolidin-4-yl, 2,4-dioxo-thiazolidin-5-yl, 4-oxo-2-thioxo-thiazolidin-5-yl, 3-methyl-2,5-dioxo-imidazolidin-4-yl, 3-methyl-2,4-dioxo-thiazolidin-5-yl, 3-ethyl-2,5-dioxo-imidazolidin-4-yl, 3-ethyl-2,5-dioxo-imidazolidin-4-yl, 3-ethyl-2,4-dioxo-thiazolidin-5-yl, 3-ethyl-2,5-dioxo-imidazolidin-5-yl.

Serial No.: 10/541,657 Filed: March 3, 2006 Page: 11 of 49

49. (original) The compound according to claim 47 wherein R<sub>9</sub> is selected from the group consisting of 1H-imidazol-4-yl, [1,2,4]triazol-1-yl, [1,2,3]triazol-1-yl, [1,2,4]triazol-4-yl, pyrrol-1-yl, pyrazol-1-yl, 1H-pyrazol-3-yl, imidazol-1-yl, oxazol-5-yl, oxazol-2-yl, [1,3,4]oxadiazol-2-yl, [1,3,4]thiadiazol-2-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]thiadiazol-3-yl, tetrazol-1-yl, pyrimidin-5-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl, 1,3-dioxo-1,3-dihydro-isoindol-2-yl and [1,2,3]thiadiazol-4-yl.

- 50. (original) The compound according to claim 42 wherein R<sub>9</sub> is C<sub>1-8</sub> alkyl or C<sub>1-4</sub> alkoxy optionally substituted with 1 to 5 substituents selected independently from the group consisting of C<sub>1-5</sub> acyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylcarboxamide, C<sub>1-4</sub> alkylsulfonyl, carbo-C<sub>1-6</sub>-alkoxy, carboxamide, carboxy, cyano, and hydroxyl.
- (original) The compound according to claim 50 wherein R<sub>9</sub> is selected from the group consisting of CH<sub>2</sub>OCH<sub>3</sub>, CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>.
- 52. (original) The compound according to claim 42 wherein  $R_9$  is of Formula (**D**):

wherein:

"p" and "r" are independently 0, or 1; and

 $R_{18}$  is H, carbo- $C_{1-6}$ -alkoxy, heteroaryl or phenyl, and wherein the heteroaryl and phenyl are each optionally substituted with 1 to 5 substituents selected independently from the group consisting of  $C_{1-4}$  alkoxy, amino,  $C_{1-4}$  alkylamino,  $C_{2-6}$  alkynyl,  $C_{2-8}$  dialkylamino, halogen,  $C_{1-4}$  haloalkoxy,  $C_{1-4}$  haloalkyl and hydroxyl.

- 53. (original) The compound according to claim 52 wherein p = 0 and r = 0.
- 54. (original) The compound according to claim 53 wherein R<sub>18</sub> is phenyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of C<sub>1-4</sub> alkoxy, amino, C<sub>1-4</sub>

Serial No.: 10/541,657 Filed: March 3, 2006 Page: 12 of 49

alkylamino,  $C_{2-6}$  alkynyl,  $C_{2-8}$  dialkylamino, halogen,  $C_{1-4}$  haloalkoxy,  $C_{1-4}$  haloalkyl and hydroxyl.

- 55. (original) The compound according to claim 52 wherein p = 0 and r = 1.
- 56. (original) The compound according to claim 55 wherein  $R_{18}$  is carbo- $C_{1-6}$ -alkoxy or carboxy.
- 57. (previously presented) The compound according to claim 43 wherein R<sub>9</sub> is substituted at the para position on the phenyl.
- 58. (previously presented) The compound according to claim 42 wherein R<sub>10</sub>-R<sub>13</sub> are independently selected from the group consisting of C<sub>1-5</sub> acyl, C<sub>1-4</sub> alkoxy, C<sub>1-8</sub> alkyl, C<sub>1-4</sub> alkylcarboxamide, C<sub>1-4</sub> alkylureyl, carbo-C<sub>1-6</sub>-alkoxy, carboxamide, carboxy, cyano, C<sub>3-6</sub> cycloalkyl, halogen, C<sub>1-4</sub> haloalkoxy and C<sub>1-4</sub> haloalkyl.
- 59. (previously presented) The compound according to claim 42 wherein one or two R<sub>10</sub>-R<sub>13</sub> groups are independently halogen.
- 60. (previously presented) The compound according to claim 42 wherein two adjacent R<sub>10</sub>-R<sub>11</sub> groups together with the phenyl form a 5, 6 or 7 membered cycloalkyl, cycloalkenyl or heterocyclic group wherein the 5, 6 or 7 membered group is optionally substituted with halogen.
- 61. (original) The compound according to claim 60 wherein the heterocyclic group together with the phenyl group is a 2,3-dihydro-benzofuran-5-yl, benzo[1,3]dioxol-5-yl group, 2,3-dihydro-benzo[1,4]dioxin-6-yl, 2,3-dihydro-benzo[1,4]dioxin-2-yl group, 3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl group.
- 62. (withdrawn) The compound according to claim 1 wherein Ar<sub>1</sub> is heteroaryl optionally substituted with R<sub>9</sub>-R<sub>13</sub>.
- 63. (withdrawn) The compound according to claim 62 wherein R<sub>9</sub> is selected from the group consisting of C<sub>1-4</sub> alkoxy, C<sub>1-8</sub> alkyl, C<sub>1-4</sub> alkylcarboxamide, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> haloalkyl, hydroxy, halogen, and phenyl.

Serial No. : 10/541,657 Filed : March 3, 2006 Page : 13 of 49

64. (withdrawn) The compound according to claim 63 wherein R<sub>9</sub> is selected from the group consisting OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, OCH(CH<sub>3</sub>)<sub>2</sub>, OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, C(O)NHCH<sub>2</sub>CH<sub>3</sub>, C(O)NHCH<sub>2</sub>CH<sub>3</sub>, C(O)NHCH<sub>2</sub>CH<sub>3</sub>, C(O)NHCH<sub>2</sub>CH<sub>3</sub>, C(O)NHCH<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, S(O)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, Cl, F, Br, CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>CF<sub>3</sub>, and hydroxy.

- 65. (withdrawn) The compound according claim 62 wherein R<sub>10</sub>-R<sub>13</sub> are independently C<sub>1-5</sub> acyl, C<sub>1-4</sub> alkoxy, C<sub>1-8</sub> alkyl, C<sub>1-4</sub> alkylcarboxamide, C<sub>1-4</sub> alkylureyl, carbo-C<sub>1-6</sub>-alkoxy, carboxamide, carboxy, cyano, C<sub>3-6</sub> cycloalkyl, halogen, C<sub>1-4</sub> haloalkoxy and C<sub>1-4</sub> haloalkyl.
- 66. (withdrawn) The compound according to claim 62 wherein one or two R<sub>10</sub>-R<sub>13</sub> groups are independently halogen.
- 67-72. (cancelled).
- 73. (previously presented) The compound according to claim 1, selected from the following compounds and pharmaceutically acceptable salts, hydrates, and solvates thereof:
  - 1-[6-(4-Imidazol-1-yl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
  - 1-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
  - 1-[6-(4-Methanesulfonyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
  - 1-{6-[4-(2-Methoxycarbonyl-acetyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
  - 1-[5-Amino-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
  - 1-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-(2,2,2-trifluoro-acetylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
  - Propionic acid 1-[2-amino-5-formyl-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin-4-yl]-piperidin-4-yl ester;

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 14 of 49

- 4-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperazine-1-carboxylic acid ethyl ester;
- 1-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid methyl ester;
- 1-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-3-carboxylic acid ethyl ester;
- 1-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethylamide;
- 1-[6-(2-Methyl-5-phenyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Bromo-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Acetylamino-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Diacetylamino-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid;
- 1-[5-Di-(methanesulfonyl)amino-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Nitro-6-(3-trifluoromethyl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Methyl-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Nitro-6-(2-trifluoromethyl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Nitro-6-(4-trifluoromethyl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
  - 1-[6-(4-Fluoro-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(2,5-Dimethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 15 of 49

1-[6-(4-Bromo-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;

- 1-[6-(4-Chloro-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4-Carbamoyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-{6-[4-(2-Methoxy-ethyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4-Cyclopentyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Nitro-6-(4-pyrrol-1-yl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4-Benzoyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-{6-[4-(4-Hydroxy-benzenesulfonyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4'-Cyano-biphenyl-4-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(2-Amino-4-ethanesulfonyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-{6-[4-(5-Hydroxy-pyrimidin-2-yl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
  - 1-[5-Nitro-6-(4-sulfo-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Nitro-6-(4-[1,2,4]triazol-1-yl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4-Carbamoylmethyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-{6-[4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4'-Methoxy-biphenyl-4-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 16 of 49

1-{6-[4-(2,5-Dioxo-imidazolidin-4-yl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;

- 4-(4,4-Difluoro-piperidin-1-yl)-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidine;
- 1-{5-Nitro-6-[4-(4-oxo-cyclohexyl)-phenoxy]-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- 1-{5-Nitro-6-[4-(3-oxo-butyl)-phenoxy]-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Nitro-6-(4-propionyl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester:
- 1-[5-Nitro-6-(4-[1,2,3]thiadiazol-4-yl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-{6-[4-(2-Hydroxy-ethyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- {4-[6-(4,4-Difluoro-piperidin-1-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-phenyl-methanone;
- 3-{4-[6-(4,4-Difluoro-piperidin-1-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-3-oxo-propionic acid methyl ester;
- 2-[6-(4,4-Difluoro-piperidin-1-yl)-5-nitro-pyrimidin-4-yloxy]-5-ethanesulfonyl-phenylamine;
  - 4-(4-Cyclopentyl-phenoxy)-6-(4,4-difluoro-piperidin-1-yl)-5-nitro-pyrimidine;
- 1-[6-(2,6-Dichloro-4-methanesulfonyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-{6-[4-(4-Chloro-benzoyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- 1-{6-[4-(4-Hydroxy-benzoyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4-Cyanomethyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- (4-{6-[4-(2-Methanesulfonyl-ethyl)-piperazin-1-yl]-5-nitro-pyrimidin-4-yloxy}-phenyl-phenyl-methanone;

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 17 of 49

4-(4-{6-[4-(2-Methanesulfonyl-ethyl)-piperazin-1-yl]-5-nitro-pyrimidin-4-yloxy}-phenyl)-butan-2-one;

- 3-(4-{6-[4-(2-Methanesulfonyl-ethyl)-piperazin-1-yl]-5-nitro-pyrimidin-4-yloxy}-phenyl)-3-oxo-propionic acid methyl ester;
- 4-(4-Methyl-piperidin-1-yl)-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidine;
- 4-(4-Bromo-piperidin-1-yl)-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidine;
- 4-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-6-(4-propyl-piperidin-1-yl)-pyrimidine;
- 1-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid amide;
- 1-[5-Nitro-6-(2-oxo-2H-chromen-6-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Nitro-6-(9-oxo-9H-fluoren-2-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-{5-Amino-6-[4-(3-oxo-butyl)-phenoxy]-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-[4-(3-Oxo-butyl)-phenoxy]-5-(2,2,2-trifluoro-acetylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-{5-Amino-6-[4-(hydroxy-phenyl-methyl)-phenoxy]-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(2-Benzoyl-5-methoxy-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(6-Chloro-pyridin-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(Benzo[1,3]dioxol-5-yloxy)-5-nitro-pyrimidin-4-yI]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4-Benzyloxy-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;

Serial No.: 10/541,657 Filed: March 3, 2006 Page: 18 of 49

1-[6-(3-Morpholin-4-yl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;

- 1-[5-Nitro-6-(4-trifluoromethylsulfanyl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Nitro-6-(4-trifluoromethoxy-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4-Benzoyl-phenoxy)-5-(2,2,2-trifluoro-acetylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
  - $\label{propyl-piperidin-1-yl-pyrimidin-4-yloxy]-phenyl} phenyl-methanone;$
- {4-Methoxy-2-[5-nitro-6-(4-propyl-piperidin-1-yl)-pyrimidin-4-yloxy]-phenyl-methanone;
  - 4-{4-[5-Nitro-6-(4-propyl-piperidin-1-yl)-pyrimidin-4-yloxy]-phenyl}-butan-2-one;
  - 5-Nitro-4-(4-propyl-piperidin-1-yl)-6-(4-[1,2,3]thiadiazol-4-yl-phenoxy)-pyrimidine;
- 3-{4-[5-Nitro-6-(4-propyl-piperidin-1-yl)-pyrimidin-4-yloxy]-phenyl}-3-oxo-propionic acid methyl ester;
- 5-Ethanesulfonyl-2-[5-nitro-6-(4-propyl-piperidin-1-yl)-pyrimidin-4-yloxy]-phenylamine;
- 2-{1-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidin-4-yl}-ethanol;
- 3-{1-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidin-4-yl}-propionic acid;
- 4-[4-(4-Methyl-benzyl)-piperidin-1-yl]-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidine;
- 4-(3-Methanesulfonyl-pyrrolidin-1-yl)-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidine;
- 4-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-6-[4-(2-trifluoromethyl-phenoxy)-piperidin-1-yl]-pyrimidine;
- 4-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-1-yl]-pyrimidine;
- 4-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-6-(4-trifluoromethyl-piperidin-1-yl)-pyrimidine;

Serial No.: 10/541,657 Filed: March 3, 2006 Page: 19 of 49

piperidin-1-yl)-pyrimidine;

4-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-6-(4-phenylsulfanyl-

- 1-[6-(3-Ethynyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4-Chloro-2-fluoro-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(2,4-Difluoro-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4-Bromo-2-fluoro-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
  - 4-(3-Ethynyl-phenoxy)-5-nitro-6-(4-propyl-piperidin-1-yl)-pyrimidine;
  - 4-(4-Chloro-2-fluoro-phenoxy)-5-nitro-6-(4-propyl-piperidin-1-yl)-pyrimidine;
  - 4-(2,4-Difluoro-phenoxy)-5-nitro-6-(4-propyl-piperidin-1-yl)-pyrimidine;
  - 4-(4-Bromo-2-fluoro-phenoxy)-5-nitro-6-(4-propyl-piperidin-1-yl)-pyrimidine;
- 4-(4-{5-Nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-1-yl]-pyrimidin-4-yloxy}-phenyl)-butan-2-one;
- 4-(4-{5-Nitro-6-[4-(2-trifluoromethyl-phenoxy)-piperidin-1-yl]-pyrimidin-4-yloxy}-phenyl)-butan-2-one;
- 4-(4-{6-[4-(3-Methyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yloxy}-phenyl)-butan-2-one;
- (4-{6-[4-(3-Methyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yloxy}-phenyl)-phenyl-methanone;
- 1-{6-[4-(4-Fluoro-benzoyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- (4-Fluoro-phenyl)-{4-[5-nitro-6-(4-propyl-piperidin-1-yl)-pyrimidin-4-yloxy]-phenyl}-methanone;
- 4-[4-(3-Methyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidine;
- 4-(4-Methoxymethyl-piperidin-1-yl)-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidine;

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 20 of 49

4-{4-[6-(4-Methoxymethyl-piperidin-1-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-butan-2-one;

4-[4-(2-Methoxy-ethyl)-piperidin-1-yl]-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidine;

4-{4-[6-(4-Ethoxymethyl-piperidin-1-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-butan-2-one;

 $4\hbox{-}(2,4\hbox{-}Difluoro\hbox{-}phenoxy)\hbox{-}5\hbox{-}nitro\hbox{-}6\hbox{-}[4\hbox{-}(pyridin\hbox{-}2\hbox{-}ylsulfanyl)\hbox{-}piperidin\hbox{-}1\hbox{-}yl]\hbox{-}pyrimidine};$ 

(4-Methoxy-2-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-1-yl]-pyrimidin-4-yloxy}-phenyl)-phenyl-methanone;

4-(2,4-Difluoro-phenoxy)-6-(4-ethoxymethyl-piperidin-1-yl)-5-nitro-pyrimidine;

4-{4-[6-(4-Cyclopropylmethoxymethyl-piperidin-1-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-butan-2-one;

4-{4-[5-Nitro-6-(4-propoxymethyl-piperidin-1-yl)-pyrimidin-4-yloxy]-phenyl}-butan-2-one;

1-{4-[6-(4-Methoxymethyl-piperidin-1-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-ethanone;

4-{4-[6-(4-Butoxymethyl-piperidin-1-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-butan-2-

one;

4-{4-[6-(4-Isobutoxymethyl-piperidin-1-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-butan-2-one;

{4-[6-(4-Ethoxy-piperidin-1-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-(4-fluoro-phenyl)-methanone;

1-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidin-4-ol;

1-[6-(4-Acetyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;

(1-{6-[4-(4-Fluoro-benzoyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidin-4-yl)-(4-fluoro-phenyl)-methanone;

 $\label{eq:condition} \mbox{$4$-(4-\{6-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yloxy}-phenyl)-butan-2-one;$ 

4-(4-Methanesulfonyl-phenoxy)-5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-1-yl]-pyrimidine;

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 21 of 49

4-(4-Methanesulfonyl-phenoxy)-5-nitro-6-[4-(pyridin-4-ylsulfanyl)-piperidin-1-yl]-pyrimidine;

4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-methanesulfonyl-phenoxy)-pyrimidine-5-carbonitrile;

1-[5-Nitro-6-(4-trifluoromethylsulfanyl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;

5-[1,3]Dioxolan-2-yl-4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-methanesulfonyl-phenoxy)-pyrimidine;

4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-methanesulfonyl-phenoxy)-pyrimidine-5-carbaldehyde;

5-[1,3]Dioxolan-2-yl-4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-[1,2,3]thiadiazol-4-yl-phenoxy)-pyrimidine;

4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-[1,2,3]thiadiazol-4-yl-phenoxy)-pyrimidine-5-carbaldehyde;

[4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-[1,2,3]thiadiazol-4-yl-phenoxy)-pyrimidin-5-yl]-methanol;

[4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-[1,2,3]thiadiazol-4-yl-phenoxy)-pyrimidin-5-ylmethyl]-dimethyl-amine;

 $\hbox{$4$-(4-Methane sulfonyl-phenoxy)-5-nitro-$6$-(4-phenyl sulfanyl-piperid in-1-yl)-pyrimid ine;}$ 

4-[4-(3-tert-Butyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(6-methanesulfonyl-pyridin-3-yloxy)-5-nitro-pyrimidine;

4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-methanesulfonyl-phenoxy)-2-methyl-pyrimidine-5-carbonitrile;

and

1-[4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-methanesulfonyl-phenoxy)-pyrimidin-5-yl]-ethanone.

74. (previously presented) The compound according to claim 1, selected from the following compounds and pharmaceutically acceptable salts, hydrates, and solvates thereof:

1-[6-(4-Bromo-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 22 of 49

1-[5-Nitro-6-(4-trifluoromethyl-phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;

- 1-[6-(Methyl-phenyl-amino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Nitro-6-(4-trifluoromethoxy-phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4-Fluoro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(3,5-Difluoro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(3,5-Dichloro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(Benzo[1,3]dioxol-5-ylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(2-Bromo-4-trifluoromethoxy-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(2-Fluoro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(3-Fluoro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-{6-[(2-Fluoro-phenyl)-methyl-amino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(Ethyl-phenyl-amino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-{6-[(4-Chloro-phenyl)-methyl-amino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-ylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-{6-[4-(Morpholine-4-sulfonyl)-phenylamino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 23 of 49

1-[6-(2,2-Difluoro-benzo[1,3]dioxol-4-ylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;

- 1-[6-(2,2-Difluoro-benzo[1,3]dioxol-5-ylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- (3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-[5-nitro-6-(4-propyl-piperidin-1-yl)-pyrimidin-4-yl]-amine;
  - (3-Fluoro-phenyl)-[5-nitro-6-(4-propyl-piperidin-1-yl)-pyrimidin-4-yl]-amine;
  - (3-Methoxy-phenyl)-[5-nitro-6-(4-propyl-piperidin-1-yl)-pyrimidin-4-yl]-amine;
- 1-{6-[(3-Fluoro-phenyl)-methyl-amino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4-Benzoyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- $1-\{6-[4-(1,1-\text{Dioxo}-1\lambda^6-\text{thiomorpholin-4-ylmethyl})-\text{phenylamino}]-5-\text{nitro-pyrimidin-4-yl}-\text{piperidine-4-carboxylic acid ethyl ester;}$
- 1-[6-(4-Methanesulfonyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- l-[6-(4-Dimethylsulfamoyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(3-Methoxy-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(2-Methoxy-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(3,5-Bis-trifluoromethyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- (4-{5-Nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-1-yl]-pyrimidin-4-ylamino}-phenyl-phenyl-methanone;
- (4-{5-Nitro-6-[4-(2-trifluoromethyl-phenoxy)-piperidin-1-yl]-pyrimidin-4-ylamino}-phenyl)-phenyl-methanone;

Serial No.: 10/541,657 Filed: March 3, 2006 Page: 24 of 49

1-[6-(4-Cyano-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;

- l-[6-(3,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4-sec-Butyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4-Heptyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Nitro-6-(3,4,5-trimethoxy-phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Nitro-6-(4-pentyl-phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-{6-[4-(3-Carboxy-propyl)-phenylamino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- 1-{6-[4-(Cyano-phenyl-methyl)-phenylamino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- 1-[6-(4-Cyclohexyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Nitro-6-(4-[1,2,4]triazol-1-yl-phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Nitro-6-(4-trifluoromethanesulfonyl-phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Nitro-6-(4-[1,2,3]thiadiazol-4-yl-phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- [6-(4-Ethoxymethyl-piperidin-1-yl)-5-nitro-pyrimidin-4-yl]-(4-methanesulfonyl-phenyl)-amine;
- [5-Nitro-6-(4-propyl-piperidin-1-yl)-pyrimidin-4-yl]-(4-[1,2,4]triazol-1-yl-phenyl)-amine;
- {5-Nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-1-yl]-pyrimidin-4-yl}-(4-[1,2,4]triazol-1-yl-phenyl)-amine;

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 25 of 49

(2-Fluoro-phenyl)-{6-[4-(3-methyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-amine;

(4-Methanesulfonyl-phenyl)-{6-[4-(3-methyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-amine;

{6-[4-(3-Methyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-(4-[1,2,4]triazol-1-yl-phenyl)-amine;

1-{5-Nitro-6-[4-(4-trifluoromethyl-phenoxy)-phenylamino]-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester:

{6-[4-(3-Ethyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-(2-fluoro-phenyl)-amine;

{6-[4-(2-Methoxy-phenylsulfanyl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-(4-[1,2,4]triazol-1-yl-phenyl)-amine;

(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-1-yl]-pyrimidin-4-yl}-amine;

(3-Methoxy-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-1-yl]-pyrimidin-4-yl}-amine;

Benzo[1,3]dioxol-5-yl-[5-nitro-6-(4-propyl-piperidin-1-yl)-pyrimidin-4-yl]-amine; (4-Fluoro-phenyl)-{1-[5-nitro-6-(4-[1,2,4]triazol-1-yl-phenylamino)-pyrimidin-4-yl]-piperidin-4-yl}-methanone;

[5-Nitro-6-(4-phenylsulfanyl-piperidin-1-yl)-pyrimidin-4-yl]-(4-[1,2,4]triazol-1-yl-phenyl)-amine;

(4-Fluoro-phenyl)-{1-[6-(2-fluoro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidin-4-yl}-methanone;

1-[6-(2-Methyl-5-phenyl-2H-pyrazol-3-ylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;

(4-Methanesulfonyl-phenyl)-[5-nitro-6-(4-phenylsulfanyl-piperidin-1-yl)-pyrimidin-4-yl]-amine;

(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(pyridin-2-yloxy)-piperidin-1-yl]-pyrimidin-4-yl}-amine;

{6-[4-(4-Fluoro-phenoxy)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-(4-methanesulfonyl-phenyl)-amine;

Serial No.: 10/541,657 Filed: March 3, 2006 Page: 26 of 49

(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(pyridin-4-yloxy)-piperidin-1-yl]-pyrimidin-4-yl}-amine;

- (4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(pyrimidin-2-yloxy)-piperidin-1-yl]-pyrimidin-4-yl}-amine;
- (4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(pyridin-4-ylsulfanyl)-piperidin-1-yl]-pyrimidin-4-yl}-amine;
- (4-Methanesulfonyl-phenyl)-{6-[4-(4-methoxy-phenylsulfanyl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-amine;
- [6-(4-Benzenesulfonyl-piperidin-1-yl)-5-nitro-pyrimidin-4-yl]-(4-methanesulfonyl-phenyl)-amine;
- {4-[6-(4-Methanesulfonyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperazin-1-yl}-acetic acid ethyl ester;
- (2-Fluoro-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-1-yl]-pyrimidin-4-yl}-amine;
- 2-Methoxy-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-1-yl]-pyrimidin-4-yl}-amine;
- {6-[4-(3-Ethyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-(4-methanesulfonyl-phenyl)-amine;
- (4-Methanesulfonyl-phenyl)-[5-nitro-6-(4-pyridin-2-ylmethyl-piperidin-1-yl)-pyrimidin-4-yl]-amine;
- 4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-methylsulfanyl-phenylamino)-pyrimidine-5-carbonitrile;
- 1-{6-[4-(4,5-Dichloro-imidazol-1-yl)-phenylamino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- Benzo[1,3]dioxol-5-yl-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-1-yl]-pyrimidin-4-yl}-amine;
- (4-Fluoro-phenyl)-{1-[6-(2-fluoro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidin-4-yl}-methanone;
- {1-[6-(Benzo[1,3]dioxol-5-ylamino)-5-nitro-pyrimidin-4-yl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone;

Serial No.: 10/541,657 Filed: March 3, 2006 Page: 27 of 49

(2,3-Difluoro-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-1-yl]-pyrimidin-4-yl}-amine;

- (2,4-Difluoro-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-1-yl]-pyrimidin-4-yl}-amine;
- (2,5-Difluoro-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-1-yl]-pyrimidin-4-yl}-amine;
- 1-[6-(4-Benzenesulfonyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-[5-Nitro-6-(2-trifluoromethyl-3H-benzoimidazol-5-ylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
- 1-{5-Nitro-6-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenylamino]-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
- {6-[4-(4-Iodo-phenoxy)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-(4-methanesulfonyl-phenyl)-amine;
- (2-Fluoro-4-methanesulfonyl-phenyl)-{6-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-amine;
- {6-[4-(3-Ethyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-(2-fluoro-4-methanesulfonyl-phenyl)-amine;
- (4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(3-propyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-pyrimidin-4-yl}-amine;
- {6-[4-(3-Cyclopropylmethyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-(4-methanesulfonyl-phenyl)-amine;
- {6-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-(4-methanesulfonyl-phenyl)-amine;
- {6-[4-(3-Cyclopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-(4-methanesulfonyl-phenyl)-amine;
- 4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-methylsulfanyl-phenylamino)-pyrimidine-5-carbonitrile;
- 4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-methanesulfinyl-phenylamino)-pyrimidine-5-carbonitrile;

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 28 of 49

(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(4-trifluoromethoxy-phenoxy)-piperidin-1-yl]-pyrimidin-4-yl}-amine;

- 4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-methanesulfonyl-phenylamino)-pyrimidine-5-carbonitrile;
- 1-{1-[6-(2-Fluoro-4-methanesulfonyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidin-4-yl}-hexan-1-one;
- 1-{1-[6-(4-Methanesulfonyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidin-4-yl}-hexan-1-one;
- {6-[4-(3-tert-Butyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-(2-fluoro-4-methanesulfonyl-phenyl)-amine;
- {6-[4-(3-tert-Butyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-(4-methanesulfonyl-phenyl)-amine;
- [6-(4-Benzofuran-2-yl-piperidin-1-yl)-5-nitro-pyrimidin-4-yl]-(4-methanesulfonyl-phenyl)-amine;
- 4-(3-Fluoro-4-methanesulfonyl-phenylamino)-6-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-pyrimidine-5-carbonitrile;
- {6-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-(5-methanesulfonyl-pyridin-2-yl)-amine;
- (3-Fluoro-4-methanesulfonyl-phenyl)-{6-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-amine;
- {6-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-(6-methanesulfonyl-pyridin-3-yl)-amine;
- 4-(2,3-Difluoro-phenylamino)-6-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-pyrimidine-5-carbonitrile;
- 4-(2,5-Difluoro-phenylamino)-6-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-pyrimidine-5-carbonitrile;
- 4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-methylsulfanyl-phenylamino)-pyrimidine-5-carbonitrile;
- 4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-methanesulfonyl-phenylamino)-pyrimidine-5-carbonitrile;

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 29 of 49

4-(4-Hexanoyl-piperidin-1-yl)-6-(6-methylsulfanyl-pyridin-3-ylamino)-pyrimidine-5-carbonitrile;

4-(4-Hexanoyl-piperidin-1-yl)-6-(6-methanesulfonyl-pyridin-3-ylamino)-pyrimidine-5-carbonitrile;

4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(6-methylsulfanyl-pyridin-3-ylamino)-pyrimidine-5-carbonitrile;

4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(6-methanesulfonyl-pyridin-3-ylamino)-pyrimidine-5-carbonitrile;

1-[4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-methanesulfonyl-phenylamino)-pyrimidin-5-yl]-ethanone;

and

1-[4-[4-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(6-methanesulfonyl-pyridin-3-ylamino)-pyrimidin-5-yl]-ethanone.

## 75-77. (cancelled)

- 78. (currently amended) A pharmaceutical composition comprising at least one compound according to claim 1, 73 or 74 and a pharmaceutically acceptable carrier.
- 79. (withdrawn, currently amended) A method for prophylaxis or treatment of a metabolic disorder in an individual comprising administering to the individual a therapeutically effective amount of a compound according to claim 1, 73 or 74 or a pharmaceutical composition thereof.
- 80. (withdrawn) The method according to claim 79 wherein the metabolic disorder is type I diabetes, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, syndrome X or metabolic syndrome.
- 81. (withdrawn) The method according to claim 79 wherein the metabolic disorder is type II diabetes.
- 82. (withdrawn, currently amended) A method for controlling or decreasing weight gain of an individual comprising administering to the individual a therapeutically effective amount of a compound according to claim 1, 73, or 74 or a pharmaceutical composition thereof.

Serial No.: 10/541,657 Filed: March 3, 2006

Page : 30 of 49

83. (withdrawn) A method of modulating a **RUP3** receptor comprising contacting the receptor with a compound according to claim 1.

- 84. (withdrawn) A method of modulating a **RUP3** receptor in an individual comprising contacting the receptor with a compound according to claim 1.
- 85. (withdrawn) The method of modulating the **RUP3** receptor according to claim 84 wherein the compound is an agonist.
- 86. (cancelled)
- 87. (withdrawn) The method of modulating the **RUP3** receptor according to claim 85 wherein the modulation of the **RUP3** receptor is prophylaxis or treatment of a metabolic disorder.
- 88. (withdrawn) The method of modulating the **RUP3** receptor according to claim 87 wherein the metabolic disorder is type I, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, syndrome X or metabolic syndrome.
- 89. (withdrawn) The method of modulating the **RUP3** receptor according to claim 87 wherein the metabolic disorder is type II diabetes.
- 90. (withdrawn) The method of modulating the RUP3 receptor according to claim 85 wherein the modulation of the RUP3 receptor controls or reduces weight gain of the individual.
- 91. (withdrawn) The method according to claim 85 wherein the individual is a mammal.
- 92. (withdrawn) The method according to claim 91 wherein the mammal is a human.
- 93-99. (cancelled)
- 100. (withdrawn, currently amended) A method of producing a pharmaceutical composition comprising admixing at least one compound according to claim 1, 73, or 74 and a pharmaceutically acceptable carrier.